Manchester, UK, 4th February 2020: EMQN CIC (“EMQN” or “the Company”), a global leader in external quality assessment (EQA) / proficiency testing (PT) for genomics, today announced it is launching a pilot EQA scheme for PIK3CA testing in patients with advanced or metastatic breast cancer.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
EMQN's scheme catalogue for 2020 is now published and available from the EMQN Home Page. Please note the purchase deadline for Germline Scheme was 30/11/2019. The deadline for Molecular Pathology* and Technical Schemes is 28/02/2020.
*PLEASE NOTE: The Lung cancer (NSCLC) Scheme 2020 is CLOSED as it is full. We cannot accept any more registrations for this schemes.
With effect from 18th January 2019, if you use the SNPCheck service, please point your browsers to its NEW web domain address by visiting the link below.
Membership of EMQN gives your laboratory access to world class resources in genomics to help improve your performance.
FINAL results from 2019 Sanger DNA sequencing EQA scheme published TODAY. Log in to your EMQN account to access the… https://t.co/2jHV7fC2az
Press release: EMQN launches pilot External Quality Assessment (EQA) scheme for PIK3CA testing in Advanced Breast C… https://t.co/HdAX6tunVJ
Press release: EMQN CIC today announced it is launching a pilot EQA scheme for PIK3CA testing in patients with adva… https://t.co/EBWPklKV1o
Example molecular pathology clinical reports now available from EMQN for its users. Read this link (… https://t.co/pkok70d5Rd
Access to quality biomarker testing in Europe. If you are a laboratory manager or pathologist working in a European… https://t.co/PA2Zgj9ZIV